Tulips Medicaments Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 26-06-2024
- Paid Up Capital ₹ 0.20 M
as on 26-06-2024
- Company Age 41 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit -14.21%
(FY 2021)
- Ebitda -10.09%
(FY 2021)
- Net Worth -15.82%
(FY 2021)
- Total Assets -2.06%
(FY 2021)
About Tulips Medicaments
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Krinita Motwani, Kirtikumar Lakdawala, and Pallavi Lakdawala serve as directors at the Company.
- CIN/LLPIN
U24239MH1983PTC029343
- Company No.
029343
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 1983
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Tulips Medicaments?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krinita Motwani  | Director | 27-Mar-2010 | Current |
| Kirtikumar Lakdawala | Director | 02-Aug-1997 | Current |
| Pallavi Lakdawala | Director | 27-Mar-2010 | Current |
Financial Performance of Tulips Medicaments.
Tulips Medicaments Pvt Ltd, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 14.21% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tulips Medicaments?
In 2021, Tulips Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ecokrin Hygiene Private LimitedActive 23 years 1 monthKrinita Motwani, Kirtikumar Lakdawala and 1 more are mutual person
- Snoval Pharmaceuticals Pvt LtdActive 41 years 10 months
Kirtikumar Lakdawala and Pallavi Lakdawala are mutual person
- Skyline Holdings Pvt LtdActive 40 years 10 days
Kirtikumar Lakdawala and Pallavi Lakdawala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tulips Medicaments?
Unlock and access historical data on people associated with Tulips Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tulips Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tulips Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
